683 Capital Management’s Greenwich LifeSciences GLSI Stock Holding History

683 Capital Management’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,604	Closed	-$206K	–	183
2023 Q4	$206K	Buy	+19,604	New	+$197K	0.02%	198
2023 Q2	–	Sell	-10,747	Closed	-$148K	–	202
2023 Q1	$148K	Sell	10,747 -953	-8%	-$15.1K	0.01%	205
2022 Q4	$178K	Buy	+11,700	New	+$134K	0.02%	194

Other funds holding GLSI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

683 Capital Management's GLSI Position: Q1 2024 in Review

683 Capital Management sold out of Greenwich LifeSciences (GLSI) in Q1 2024, closing a stake of 19,604 shares — an estimated $206K sold.

683 Capital Management first reported a position in GLSI in Q4 2022 and held it in 3 quarters. The position peaked at $206K in Q4 2023. 31 funds tracked by Wall St. Rank hold GLSI as of Q1 2024.

683 Capital Management reported no remaining Greenwich LifeSciences position as of Q1 2024 after selling out during the quarter.
683 Capital Management sold 19,604 Greenwich LifeSciences shares in Q1 2024, an estimated $206K.
683 Capital Management first reported a position in Greenwich LifeSciences in Q4 2022 and held it in 3 quarters.
683 Capital Management's Greenwich LifeSciences position peaked at $206K in Q4 2023.
31 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.